CSTL Q4 2022 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q4 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$38M+53.1% YoY

Gross Profit

$29M75.2% margin

Operating Income

-$23M-59.6% margin

Net Income

-$21M-53.8% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

+3.6%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$8M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$447M

Total Liabilities

$48M

Stockholders' Equity

$399M

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$25M	+53.1%
Gross Profit	$29M	$20M	+41.0%
Operating Income	-$23M	-$15M	-50.5%
Net Income	-$21M	-$6M	-220.7%

Revenue Segments

Dermatologic

$35M90%

Service, Other

$4M10%